Latest Dividend News

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

SSH Group Limited reported a 7% revenue decline and a 21% drop in profit after tax for FY2025, while net tangible assets per share doubled amid strategic acquisitions.

333D Limited has reported a remarkable turnaround for the year ended June 2025, posting a profit after tax of $143,777 on the back of a 426% revenue increase driven by its digital asset management strategy. The company also adopted a Bitcoin Treasury Management Policy, signaling a new phase in its financial approach.

OM Holdings reported a significant turnaround to a US$9.6 million loss in H1 2025 despite stable revenue, driven by weaker alloy prices and operational challenges. The company also announced a conditional sale of its 13% stake in the Tshipi Borwa Manganese Mine.

Humm Group Limited has announced a fully franked ordinary dividend of AUD 0.0075 per share for the six months ending June 2025, alongside a Dividend Reinvestment Plan offering.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Future Generation Global Limited has reported a 20.8% increase in its investment portfolio over the past year, prompting a boost in its fully franked interim dividend to 4.0 cents per share. This performance outpaces global market averages and underscores the company's sustainable investment approach.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Future Generation Global Limited reported a notable decline in half-year profits but raised its fully franked interim dividend, underscoring confidence in its investment strategy and ongoing commitment to youth mental health initiatives.

FOS Capital Limited reported a solid 47.5% jump in net profit for the 2025 financial year alongside a modest revenue increase, announcing a final dividend of 1 cent per share.